Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

BCL-2–Selective Inhibitors Spare Platelets

DOI: 10.1158/2159-8290.CD-RW2013-012 Published March 2013
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Reverse engineering of navitoclax identified a BCL-2–selective inhibitor that does not kill platelets.

  • Concept: Navitoclax blocks the activity of both BCL-2 and BCL-XL, the primary platelet survival factor.

  • Impact: A selective BCL-2 inhibitor can be used at relatively high doses without causing thrombocytopenia.

Prosurvival BCL-2 family proteins that mediate evasion of apoptosis are often required for cancer cell survival and represent attractive therapeutic targets. The orally bioavailable small molecule navitoclax (ABT-263) inhibits the antiapoptotic activity of the highly related proteins BCL-2 and BCL-XL and has shown clinical activity in BCL-2–dependent hematologic cancers. However, BCL-XL is also a key survival factor for platelets, and BCL-XL inhibition by navitoclax leads to a rapid decrease in circulating platelets, or thrombocytopenia, that limits dosing. Souers and colleagues therefore hypothesized that a selective BCL-2 inhibitor might be used at more effective doses in BCL-2–dependent cancers without on-target thrombocytopenia. Systematic removal or replacement of navitoclax moieties to identify features that increased BCL-2 selectivity led to the discovery of ABT-199, a small molecule with subnanomolar affinity for BCL-2. ABT-199 potently disrupted BCL-2 function and induced apoptotic cell death, particularly in leukemia and lymphoma cells with high BCL-2 expression. Single-agent ABT-199 suppressed growth of several hematologic tumor xenograft models in a dose-dependent manner and potentiated the activity of clinically relevant chemotherapies and immunotherapies such as bendamustine and rituximab. Importantly, ABT-199 was significantly less active against human platelets ex vivo than navitoclax and could be used at much higher doses in dogs without appreciable effects on circulating platelets, suggesting that efficacious plasma concentrations of ABT-199 might be attained without platelet damage. Indeed, in a first-inhuman trial in 3 patients with refractory chronic lymphocytic leukemia, a single dose of ABT-199 induced tumor lysis in all 3 patients with in 24 hours with minimal effects on platelet counts. BCL-2–selective inhibition may therefore be feasible for treatment of BCL-2–dependent cancers and avoid ontarget toxicity associated with inhibition of BCL-XL.

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202–8.

Notes

Note: Research Watch is written by Cancer Discovery Science Writers. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

  • ©2012 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (3)
March 2013
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BCL-2–Selective Inhibitors Spare Platelets
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BCL-2–Selective Inhibitors Spare Platelets
Cancer Discov March 1 2013 (3) (3) 247; DOI: 10.1158/2159-8290.CD-RW2013-012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BCL-2–Selective Inhibitors Spare Platelets
Cancer Discov March 1 2013 (3) (3) 247; DOI: 10.1158/2159-8290.CD-RW2013-012
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Targeted Therapy

  • REV1–POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity
  • Sequential Inhibition of PARP and WEE1 Minimizes Toxicity
  • Non–Cell Autonomous NK Cell Effects Underlie Combination Therapy Efficacy
Show more Targeted Therapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement